Background and Aims Smokers can regulate their nicotine intake by altering the number of cigarettes smoked per day
INTRODUCTION
Maternal cigarette smoking is the leading preventable cause of poor pregnancy outcomes [1] , yet approximately 14% of pregnant women are regular cigarette smokers [2] . On average, only 40% of women quit smoking during pregnancy, with more than 90% relapsing within 1 year [3] . Compared to pregnant women who continue to smoke during pregnancy, those who quit have more favorable smoking behaviors (e.g. smoking fewer cigarettes per day, reporting higher motivation for abstinence and less dependency) [4] .
A dose-effect relationship exists between nicotine intake and smoking-related outcomes of pregnancy [5] [6] [7] [8] .
Smokers can regulate their nicotine intake to maintain relatively constant circulating nicotine levels throughout the day by altering the number of cigarettes they smoke per day (CPD) and their smoking intensity, including puff frequency, volume and duration. Nicotine intake is quantified most commonly by self-reported CPD [9] [10] [11] . Despite the simplicity of collecting CPD data, CPD remains a crude measure of nicotine intake as it does not take into account smoking intensity, which can alter nicotine intake per cigarette. The best biochemical biomarker of nicotine intake is determined by the molar sum of nicotine and metabolites in urine and is referred to as total nicotine equivalents (TNE) [12, 13] . Following smoking in 12 nonpregnant smokers, approximately 88% of the systemic nicotine dose was accounted for by urinary TNE [13] . A second widely used biochemical measure of nicotine intake is nicotine's primary metabolite, cotinine [14, 15] . Cotinine has a relatively long half-life (~16 hours), suggesting that cotinine can be detected for a few days after smoking cessation [14, 15] .
Nicotine is metabolized primarily by hepatic CYP2A6, and nicotine's major metabolite, cotinine, is metabolized exclusively by CYP2A6 to trans-3 0 -hydroxycotinine (3HC) [16] [17] [18] . Due to the long half-life of cotinine and the 3HC formation dependency, the ratio of nicotine's metabolites 3HC/cotinine, referred to as nicotine metabolic ratio (NMR), functions as a surrogate measure of the rate of nicotine metabolism [19] [20] [21] . The rate of nicotine metabolism is correlated highly with CYP2A6 enzymatic activity and has been identified as an important factor influencing nicotine intake [22, 23] . CYP2A6 activity is influenced by a variety of genetic (i.e. polymorphisms) and non-genetic (i.e. diet, medications, sex) factors [24] . Individuals who metabolize nicotine faster (who have higher CYP2A6 activity and NMR) smoke more to maintain similar levels of nicotine in the body compared to slower nicotine metabolizers (who have lower CYP2A6 activity and NMR) [22, 23, 25] . The rate of nicotine metabolism is accelerated during pregnancy, as evidenced by faster nicotine clearance [26] and a lower proportion of nicotine excreted unchanged (as a fraction of TNE) [27] . Estrogen levels begin to rise after conception and are approximately five-and 20-fold higher at early and late pregnancy, respectively, compared to pre-pregnancy levels [27] . Elevated estrogen during pregnancy is thought to induce CYP2A6 and UGT2B10 enzymatic activity, leading to accelerated nicotine metabolism by increasing the rate of nicotine and cotinine C-oxidation and N-glucuronidation, respectively; the increase in nicotine metabolism rate is even greater at late compared to early pregnancy stages [27] . Consistent with elevated CYP2A6 activity during pregnancy, pregnant smokers have higher NMR compared to non-pregnant women [28, Arger et al., unpublished] , suggesting that they may increase their smoking to maintain similar nicotine levels and may need to be treated with higher doses of NRT. Elevated rates of nicotine metabolism may further influence the ability of biomarkers to accurately estimate nicotine intake during pregnancy. TNE is not impacted substantially by variation in the rate of nicotine and cotinine metabolism, as the parent substrates and resulting metabolite levels are assessed together [29, 30] . Unlike TNE, there is individual variability in the quantitative relationship between steady state cotinine concentrations and intake of nicotine. This is because people convert different percentages of nicotine to cotinine (range = 50-90%) and metabolize cotinine at different rates (clearance range = 20-75 ml/minute) [13, 16] . For example, individuals with higher CYP2A6 activity have lower ratios of cotinine formation to cotinine removal (i.e. relatively lower cotinine levels for a given nicotine intake) compared to individuals with lower CYP2A6 activity [31] . Similarly, pregnant smokers who have higher CYP2A6 and UGT2B10 activity may have relatively lower cotinine levels for the same intake of nicotine. Thus, cotinine is a weaker biomarker than TNE, but it is unclear by how much cotinine underestimates nicotine intake in pregnant smokers and how this may be affected at different stages of pregnancy.
The objective of this study was to investigate the utility of biomarkers to estimate nicotine intake accurately during pregnancy. We aimed to (1) compare self-reported CPD, TNE, TNE/CPD (i.e. nicotine intake per self-reported CPD) and urinary cotinine during early pregnancy, late pregnancy and postpartum. (2) We then aimed to measure the extent to which cotinine underestimates nicotine intake at each pregnancy stage and (3) among those with slower versus faster nicotine metabolism.
METHODS

Trial design
Current smoking pregnant women (n = 118) were recruited from obstetric practices in Burlington, VT to participate in a smoking cessation trial to examine the efficiency of voucher-based incentives for decreasing smoking during pregnancy [32] . The inclusion criteria for the parent trial were self-reported smoking in the past 7 days, urinary cotinine > 80 ng/ml and gestational age ≤ 25 weeks. The exclusion criteria for the parent trial included selfreported use of prescribed opioid, psychomotor stimulant or anti-psychotic medications. The recruitment period for the parent trial was December 2006 to June 2012. The follow-up rate for the 6 months postpartum assessment was 71% for the incentive arm and 69% for the nonincentive arm. Women who terminated the pregnancy or had a fetal demise post-randomization were withdrawn from the parent trial. A subset of participants (n = 47; n = 27 from incentive arm and n = 20 from non-incentive arm) met the inclusion criteria for the current analysis, which included providing a spot urine sample at all three trial assessments conducted during early pregnancy [estimate gestational age (EGA) = 12.5 ± 4.5 weeks], late pregnancy (EGA = 28.9 ± 2.0 weeks) and at 6 months postpartum (24.7 ± 1.2 weeks since birth). The final sample of 47 provided 89% power to detect differences in TNE between stages of pregnancy (effect size~0.39; G*Power 3.1.9.3; Heinrich-Heine-Universität, Dusseldorf, Gernamy) [33] . No participants were taking any forms of NRT. Demographic characteristics for the subset of participants included in the current analysis (n = 47) are presented in Table 1 . The University of Toronto and University of Vermont Institutional Review Boards approved this study and all participants provided written informed consent.
Analytical procedures
Spot urine samples (5 ml) were collected, frozen and sent to University of Toronto for nicotine metabolite assessment. TNE was analyzed in urine using liquid chromatography tandem mass spectrometry (LC-MS/MS), as described previously [34] . Urinary creatinine concentrations were determined using a colorimetric assay (Creatinine Assay Kit MAK080) from Sigma (St Louis, MO, USA) with a SynergyMX Analyzer (BioTek, Winooski, VT, USA) and were adjusted for the effect of pregnancy on creatinine clearance (i.e. scaled creatinine), as described previously [27, 35] .
Measures
We assessed nicotine intake at each pregnancy stage with the following variables: CPD and urinary biomarkers of nicotine consisting of TNE, free cotinine and total cotinine. CPD was assessed by self-report. TNE was quantified as the molar sum of nicotine and nine metabolites (free cotinine, free 3HC, nicotine glucuronide, cotinine glucuronide, 3HC glucuronide, nicotine N-oxide, cotinine N-oxide, nornicotine and norcotinine). Total cotinine was quantified as the molar sum of free cotinine and cotinine glucuronide. Nicotine intake per self-reported CPD was assessed by the ratio of TNE per CPD.
The NMR was determined as the ratio of 3HC + 3HC glucuronide/free cotinine in urine. Nicotine metabolism status was determined by a median split on the NMR measured at postpartum [36] , and participants were categorized into a slower (NMR ≤ 4.6, n = 24) versus faster strata (NMR > 4.6, n = 23) (Supporting information, Fig. S3 ).
Data analysis
Urinary TNE, free cotinine, and total cotinine were corrected for creatinine using scaled creatinine concentrations [27, 35] . All biomarkers were measured three times, at early and late pregnancy and at 6 months postpartum. Additionally, a retrospective report of pre-pregnancy CPD was collected at the time of entry into the trial during early pregnancy. General linear repeated-measures analysis with Bonferroni correction was used to compare changes in nicotine intake longitudinally throughout the four (for CPD) and three (for all other biomarkers) timepoints. As participants in the incentive arm may be more motivated to under-report their smoking quantity compared to those in the non-incentive arm, the relationship between TNE and CPD was tested separately in subjects from these two arms. No significant difference in nicotine intake per cigarette between the two groups was observed (Supporting information, Fig. S1 ). Furthermore, more dependent smokers [i.e. those with higher Fagerström Test for Nicotine Dependence (FTND scores] may be more prone to adopting compensatory smoking styles during pregnancy. As such, the relationship between TNE and CPD was tested in those who reported smoking within the first hour of waking (i.e. time to first cigarette < 60 minutes; a component of FTND) compared to those smoking their first cigarette later in the day. No significant difference in nicotine intake per cigarette between the two groups was observed (Supporting information, Fig. S2 ). Spearman's correlation was used to evaluate the relationship between (1) free cotinine and TNE and (2) total cotinine and TNE. Linear regression was used to calculate the slopes (± standard error of the slopes) for the relationship between TNE, free cotinine and total cotinine. All analyses were conducted with GraphPad Prism version 5.0 (La Jolla, CA, USA) and SPSS version 24.0 (IBM, Armonk, NY, USA). Intake refers to when subjects were enrolled in the study during early pregnancy (estimated gestational age mean 12.5 ± standard deviation 4.5 weeks).
RESULTS
Changes in self-reported CPD during pregnancy
Pregnant smokers reported smoking 19.6 CPD prior to pregnancy, 10.4 CPD at early pregnancy (a 47% reduction, P < 0.001), 7.2 CPD at late pregnancy (further 31% reduction, P = 0.001) and 8.6 at postpartum (a 19% increase, P = 0.08) ( Table 2 , Figure 1a ).
Changes in TNE during pregnancy TNE was, on average, 11% lower at late pregnancy compared to early pregnancy (P = 0.32), suggesting a modest reduction in intake between these two pregnancy stages. TNE exposure was 41% (P = 0.07) and 48% (P = 0.03) lower at early and late pregnancy, respectively, compared to postpartum (Table 2 , Fig. 1b) , suggesting a relatively large increase in intake between pregnancy and postpartum.
Changes in nicotine intake per cigarette during pregnancy
Despite reporting smoking fewer CPD, nicotine intake per self-reported CPD was on average 167% (2.67-fold) higher (as measured by the ratio of TNE per CPD for each subject which was then averaged across all 47 subjects) at late pregnancy compared to early pregnancy (P = 0.01). Nicotine intake per self-reported CPD remained relatively high at postpartum where it was 111% (2.1-fold) higher compared to early pregnancy (P = 0.007) ( Table 2 , Fig. 1c ).
Changes in urinary cotinine during pregnancy
The quantitative relationship between nicotine intake (i.e. TNE exposure) with free cotinine is presented in Fig. 2a .
Free cotinine was correlated highly with TNE at all three pregnancy stages (Spearman's rho = 0.77-0.84, all P-values < 0.0001). Independent regression lines between urinary TNE and free cotinine were constructed for each stage of pregnancy (n = 47 for each stage). The slope of the regression lines in early and late pregnancy was significantly lower than the slope in postpartum (slope: 0.09 and 0.07 in early and late pregnancy, respectively, versus 0.20 in postpartum, P < 0.001), with a statistically significant interaction between pregnancy stage and free cotinine levels in the linear regression analysis with TNE as the dependent variable (P interaction < 0.001; Table-3) . These observations indicate that free cotinine predicts nicotine intake differently at different stages of pregnancy. As illustrated in Fig. 2a , a 200 nmol/mg creatinine TNE exposure was suggestive of an 18 and 14 nmol/mg creatinine free cotinine level at early and late pregnancy, whereas the same TNE exposure was indicative of 40 nmol/mg creatinine cotinine level at postpartum. This reflects, on average, 55 and 65% underestimation of nicotine intake by free cotinine at early and late pregnancy compared to postpartum.
Changes in urinary cotinine by nicotine metabolism status during pregnancy
Cotinine levels, as a measure of intake, may be affected differentially in individuals with lower versus higher NMR. A difference in regression line slopes was observed between pregnancy stages in the slower NMR strata (n = 24) (slope: 0.11 and 0.08 in early and late pregnancy, respectively, versus 0.15 in postpartum, P interaction < 0.001; Table 3 and Fig. 2c) . A 200 nmol/mg creatinine TNE exposure was suggestive of a 22 and 16 nmol/mg creatinine free cotinine level at early and late pregnancy, whereas the same TNE exposure was indicative of 30 nmol/mg creatinine free cotinine at postpartum. In the slower NMR strata this reflects, on P-values are for the main effect of time and are derived from repeated-measures general linear modeling corrected for age of smoking initiation, age at intake, ethnicity, years of education and Minnesota Nicotine Withdrawal Scale (MNWS) scores. Statistical testing was performed on non-log-transformed values with the exception of the nicotine metabolic ratio (NMR). However, when tested on log-transformed values, the P-values did not differ substantially from those reported here on non-logged data.
b Intake refers to when subjects were enrolled into the study during early pregnancy (estimated gestational age mean 12.5 ± SD 4.5 weeks). Prior to pregnancy refers to retrospective assessment of the number of cigarettes smoked before enrollment in the study when subjects were not pregnant. c Urinary total nicotine equivalents, free cotinine and total cotinine (nmol/mg creatinine) were corrected for creatinine using creatinine values that were adjusted for the effect of pregnancy. Same data uncorrected for creatinine, or corrected for creatinine using creatinine values unadjusted for the effect of pregnancy on creatinine clearance, are presented in Supporting information, Table S1 . average, 27 and 47% underestimation of nicotine intake by free cotinine compared to when TNE is used at early and late pregnancy compared to postpartum.
A similar, albeit smaller, difference in regression line slopes was observed between the stages of pregnancy in the faster NMR strata (slope: 0.07 and 0.06 in early and late pregnancy, respectively, versus 0.09 in postpartum, P interaction = 0.04; Table 3 and Fig. 2e) . A 200 nmol/mg creatinine TNE exposure was indicative of a 14 and 12 nmol/mg creatinine free cotinine level at early and late pregnancy, whereas the same Figure 1 Nicotine intake measured by cigarettes per day (CPD) (a), total nicotine equivalents (TNE) (b) and smoking intensity estimated by TNE/ CPD (c) during pregnancy and postpartum.Individual longitudinal data are presented, in addition to mean ± standard deviation (SD). Statistical testing was performed on all n = 47 subjects at all three stages, but one outlier from early pregnancy and two from postpartum were removed from the illustrations in (a) and (b), respectively. P-values are for between-stage comparisons and are derived from repeated measures general linear modeling (Bonferroni correction). CI = confidence interval Figure 2 Left: free cotinine's ability to predict tobacco exposure was different between stages of pregnancy (a) and by nicotine metabolism status (c,e). Right: total cotinine's (i.e cotinine + cotinine glucuronide) ability to predict tobacco exposure was not different between stages of pregnancy (b) or by nicotine metabolism status (d,f). The slope between urinary total nicotine equivalents (TNE) and urinary total cotinine was not different between stages of pregnancy (trend lines derived from linear regression modeling are overlapping). The same data analysis, uncorrected for creatinine (free and total cotinine in ng/ml and TNE in nmol/l), can be found in Supporting information, Fig. S5 . Nicotine metabolism status was determined by a median split on the nicotine metabolite ratio at 6 months postpartum, an approximation of baseline nicotine metabolic ratio (NMR) during non-pregnancy. The numbers after the slopes are standard error TNE exposure was indicative of 18 nmol/mg creatinine free cotinine at postpartum. In the faster NMR strata this reflects, on average, 22 and 33% underestimation of nicotine intake by free cotinine compared to when TNE is used at early and late pregnancy compared to postpartum.
Compared to free cotinine, total cotinine may be a better biomarker for measuring nicotine intake, in part because it takes into account variation in removal of cotinine via glucuronidation, which is increased in pregnancy via induction of UGT2B10 [27] . The quantitative relationship between TNE and total cotinine is presented in Fig. 2b . Total cotinine was highly correlated with TNE at all three pregnancy stages (Spearman's rho = 0.94-0.96, all P < 0.0001). Similar to free cotinine, independent regression lines between urinary TNE and total cotinine were constructed for each stage of pregnancy. The slopes of the regression lines were not different between early pregnancy, late pregnancy and postpartum (slope: 0.35 and 0.33 in early and late pregnancy, respectively, versus 0.35 in postpartum), suggesting that total cotinine predicts nicotine intake similarly at different stages of pregnancy (Table 3 and Fig. 2b) . Similarly, there was no statistically significant difference in total cotinine estimates of dose between stages of pregnancy in the slower or faster NMR strata (Table 3 ; Fig. 2d,f) .
DISCUSSION
We found that self-reported CPD was 21% higher at early pregnancy and 16% lower at late pregnancy compared to postpartum. TNE exposure was 41 and 48% lower at early and late pregnancy, respectively, compared to postpartum. This suggests: (1) under-reporting of CPD and/or (2) an increase in nicotine intake per self-reported CPD at late pregnancy which also remained relatively high at postpartum, due potentially to more intense smoking. We found further that free cotinine underestimated nicotine intake by 55% Table 3 Regression analyses of the predictive ability of cotinine on total nicotine equivalents exposure during pregnancy.
Y = TNE
All Subjects (n = 47) r 2 = 0.87, P < 0. as early as 12 weeks' gestation during early pregnancy and by 65% by 29 weeks' gestation during late pregnancy compared to postpartum. Differential effects of the stages of pregnancy on the quantitative relationship between cotinine and TNE were larger in phenotypically slower compared to faster nicotine metabolizers. In the absence of TNE data, we found that total cotinine (free cotinine plus cotinine glucuronide) provided better estimates of nicotine intake than free cotinine reducing the effects of stages of pregnancy on the accuracy of the estimations. The self-reported CPD at each pregnancy stage matched closely those reported in many previous studies [9] [10] [11] [37] [38] [39] , suggesting, in general, that pregnant smokers report reducing their CPD substantially at early pregnancy and making further smaller reductions at late pregnancy. To our knowledge, no studies have measured nicotine intake by TNE from early pregnancy, throughout gestation and into postpartum. Despite lower self-reported CPD, we found that the TNE was relatively comparable at early and late pregnancy and substantially higher at postpartum, suggesting that intake of nicotine may be much higher than suggested by CPD. Mean TNE levels measured for non-pregnant female smokers of similar ethnicity were 37.5 nmol/l in 99 non-pregnant female smokers (average of 20 CPD) [40] . In contrast, TNE levels measured at early pregnancy, late pregnancy and postpartum in this study were 68.9, 55.8 and 82.9 nmol/l (converted to the same unit of concentration). This suggests that pregnant smokers may under-report their CPD, for example due to social pressures, which is observed frequently in studies of pregnancy [41] [42] [43] [44] ; under-reporting of CPD may also be observed during postpartum, for example due to social expectation around smoking with a newborn. This also suggests, in addition to under-reporting of CPD, that pregnant smokers may smoke each cigarette much more intensely during pregnancy and after birth. In both cases, CPD appears to underestimate nicotine intake substantially. As such, studies that estimate fetal exposure using CPD may severely underestimate the magnitude of toxic exposure [45] [46] [47] .
Our observation of the nicotine intake remaining high into the postpartum period is novel, and suggests that learning to smoke more intensely, and adaptation to sensory effects associated with more intense smoking, during pregnancy may lead to continuation of this smoking behavior well into the postpartum period. Further, it suggests that pre-pregnancy and postpartum are distinct periods in terms of smoking behaviors and that CPD may be an even poorer biomarker of nicotine intake in postpartum compared to non-pregnant female smokers. Of note, a previous study comparing puffing behavior between pregnant and non-pregnant subjects found no difference in puff frequency, volume and duration, suggesting that smoking topography was not influenced by faster nicotine metabolism during pregnancy [48] . Their study points to under-reporting of CPD being a reason for the disconnect in CPD versus TNE levels we observed, as well as potential increases in nicotine intake per self-reported CPD (TNE/CPD) due, for example, to smoking a greater portion of each cigarette. While these alternatives could be tested empirically, both indicate that CPD underestimates nicotine intake substantially relative to TNE during both pregnancy and in postpartum.
Following birth, it is unknown when nicotine metabolism rates return to pre-pregnancy levels. In this same data set, we found that the profile of nicotine and metabolites at postpartum was similar to those reported for non-pregnant populations [27] . Thus, while this postpartum time point probably differs from pre-pregnancy in terms of smoking behaviors, it appears to be a good estimate for baseline metabolic differences and for biomarker assessment (i.e. cotinine). Cotinine's underestimation of nicotine intake during pregnancy suggests that studies estimating fetal exposure using cotinine may substantially underestimate the magnitude of nicotine and toxin exposure. Furthermore, studies that use cotinine to verify smoking abstinence may inaccurately classify pregnant smokers as abstinent. For example, the cotinine cut-off of 15 ng/ml in plasma used widely to distinguish smokers from non-smokers in clinical trials is approximately equivalent to cotinine of 60 ng/mg creatinine in urine [49] . Cotinine at 60 ng/mg creatinine represents a postpartum TNE exposure of 300 nmol/mg creatinine (see Fig. 2 ). However, during pregnancy a TNE exposure of 300 nmol/mg creatinine is equivalent to urinary cotinine of 27 and 21 ng/mg creatinine at early and late pregnancy, respectively: well below the urinary cotinine cut-off of 60 ng/mg creatinine. Together, this suggests that while actively smoking based on their TNE exposure, urinary cotinine levels would have classified these pregnant smokers as non-smokers at both early and late pregnancy due to more rapid metabolism of cotinine at these times. We found that total cotinine, compared to free cotinine, was a more accurate measure of nicotine intake during pregnancy, as the quantitative relationship between total cotinine and TNE exposure at early and late pregnancy was related more closely to the relationship observed at postpartum.
A limitation of our study is that TNE data was not collected prior to pregnancy limiting our ability to biochemically verify changes in nicotine intake that occur upon learning of pregnancy (i.e. pre-pregnancy to early pregnancy). A second potential limitation is that subjects were recruited as part of a larger smoking cessation study which may have altered their smoking, thus limiting the generalizability of our findings. Moreover, subjects were not asked about use of alternative nicotine products (e.g. e-cigarettes) which could also have influenced their nicotine intake.
In conclusion, the intake of nicotine was higher during pregnancy and in postpartum than is suggested by selfreported CPD. Cotinine underestimated nicotine intake by as much as 55% as early as 12 weeks' gestation, with the underestimation increasing as pregnancy progresses. Lastly, the quantitative relationship between cotinine and TNE was affected more substantially in subjects who are slower compared to faster nicotine metabolizers. These findings provide insights into changes in smoking behaviors and utility of self-reported and biochemical biomarkers of nicotine intake during pregnancy.
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Table S1
Smoking characteristics and biomarkers (uncorrected in ng/ml and corrected in nmol/mg creatinine using creatinine levels that were not adjusted, i.e. unscaled, for the effect of pregnancy on creatinine clearance).
Figures S1 Mean ± standard deviation of nicotine intake per cigarette measured by the ratio of total nicotine equivalent/cigarettes per day (TNE/CPD) for those in the incentive (n = 27) versus non-incentive (n = 20) arms of the parent trial within each stage of pregnancy.
Figures S2 Mean ± standard deviation of nicotine intake per cigarette measured by the ratio of nicotine equivalent/cigarettes per day (TNE/CPD) for those with time to first cigarette (TFC) < 60 minutes (n = 19) versus those with TFC ≥ 60 minutes (n = 28) within each stage of pregnancy. Figure S3 Mean ± standard deviation of the nicotine metabolite ratio for slower and faster metabolism groups within each stage of pregnancy. Figure S4 Mean ± standard deviation of nicotine intake measured by cigarettes per day (CPD) (a), total nicotine equivalent (TNE) (b), free cotinine (c), and total cotinine (d) for slower (n = 24) and faster (n = 23) metabolism groups within each stage of pregnancy. The metabolism group was determined based on a median split on the nicotine metabolite ratio measured at postpartum. Figure S5 Left: free cotinine's ability to predict tobacco exposure was different between stages of pregnancy (a) and by nicotine metabolism status (c,e). Right: total cotinine's ability to predict tobacco exposure was not different between stages of pregnancy (b) or by nicotine metabolism status (d,f). The slope between urinary total nicotine equivalent (TNE) and urinary total cotinine was not different between stages of pregnancy (trend lines derived from linear regression modeling are overlapping).
